Related Experiment Video
Updated: Feb 9, 2026

Hepatic Progenitor Specification from Pluripotent Stem Cells using a Defined Differentiation System
Published on: May 10, 2020
Differential expression profile of hepatic circular RNAs in chronic hepatitis B
1Central lab, Liver disease research center, the Second People's Hospital of Yunnan Province, Kunming, China.
Insights
Circular RNAs (circRNAs) show distinct expression patterns in chronic hepatitis B (CHB) patients, impacting disease progression. These findings highlight circRNAs as potential biomarkers and therapeutic targets for CHB.
Area of Science:
- Molecular Biology
- Hepatology
- Genomics
Background:
- Circular RNAs (circRNAs) are key gene regulators, influencing disease development.
- Limited understanding of circRNA roles in chronic hepatitis B (CHB) and healthy states.
Purpose of the Study:
- To identify hepatic circRNAs associated with CHB.
- To analyze circRNA-miRNA-mRNA pathways in CHB pathogenesis.
Main Methods:
- RNA sequencing of liver biopsies from CHB patients and controls.
- Bioinformatics pipeline for circRNA identification and pathway analysis.
- Quantitative reverse transcription polymerase chain reaction (qRT-PCR) for validation.
Main Results:
- Significant differences in hepatic circRNA expression profiles between CHB patients and controls.
- Identified 99 dysregulated circRNAs correlated with CHB.
- Revealed 665 microRNAs (miRNAs) targeted by differentially expressed circRNAs.
- Four circRNA-miRNA-mRNA pathways implicated in HBV infection and liver disease progression.
- Discovered a specific pathway involving hsa_circ_0000650, miR-6873-3p, and TGFβ2.
Conclusions:
- CHB patients exhibit unique hepatic circRNA expression and interaction profiles.
- CircRNAs represent promising novel mechanisms in CHB pathogenesis and progression.
- CircRNAs and their interactions offer potential as CHB biomarkers and therapeutic targets.
Abstract:
CircRNAs exert gene regulatory effects by sequestering target microRNAs (miRNAs) and play a vital role in the onset and development of disease. Until recently, little has been known about the expression, regulation and biological function of circRNAs in both health and chronic hepatitis B (CHB).To identify hepatic circRNAs associated with CHB, we performed RNA sequencing using liver biopsies from untreated CHB patients and controls. We then established a bioinformatics pipeline for identification of CHB-associated circRNAs and in silico analysis of the circRNA-miRNA-mRNA pathways. We used quantitative reverse transcription polymerase chain reaction (qRT-PCR) to confirm these results. The profiles of hepatic circRNA expression were significantly different in CHB compared with controls, with a total of 99 dysregulated circRNAs identified to be correlated with CHB. Computational analysis of the circRNA-miRNA-mRNA pathways revealed a large number of miRNAs (665), which were putatively targeted by the differentially expressed hepatic circRNAs. Interestingly, four of the predicted CHB-related circRNA-miRNA-mRNA pathways were found to be involved in the pathogenesis of HBV infection and progression of HBV-associated liver disease. Among these pathways, regression analysis of gene expression revealed a strong positive correlation between hsa_circ_0000650 and TGFβ2 and a negative correlation between hsa_circ_0000650 and miR-6873-3p, which hinted that hsa_circ_0000650 interacted with TGFβ2 mediated by miR-6873-3p. This study firstly demonstrates that patients with CHB present different profiles of hepatic circRNAs and circRNA/miRNA interactions. Thus, circRNAs have promise as novel mechanisms underlying the pathogenesis and progression of CHB.
More Related Videos
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic Portal System
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Hepatic Drug Excretion: Influencing Factors
Hepatic Drug Clearance: Role of Transporters
Hepatic Drug Excretion: Enterohepatic Cycling
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...

